Cetera Investment Advisers
CPRX

Cetera Investment Advisers’s Catalyst Pharmaceutical CPRX Stock Holding History

Cetera Investment Advisers’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$565K Sell
17,977
-40,671
-69% -$1.2M ﹤0.01% 3587
2026
Q1 		$1.45M Buy
58,648
+2,612
+5% +$62.2K ﹤0.01% 2570
2025
Q4 		$1.31M Buy
56,036
+3,557
+7% +$79.2K ﹤0.01% 2598
2025
Q3 		$1.03M Sell
52,479
-2,249
-4% -$46.3K ﹤0.01% 2742
2025
Q2 		$1.19M Sell
54,728
-3,452
-6% -$81.5K ﹤0.01% 2229
2025
Q1 		$1.41M Buy
58,180
+15,066
+35% +$339K ﹤0.01% 1996
2024
Q4 		$900K Buy
43,114
+11,221
+35% +$241K ﹤0.01% 2230
2024
Q3 		$634K Sell
31,893
-2,053
-6% -$38.1K ﹤0.01% 2461
2024
Q2 		$526K Buy
33,946
+5,197
+18% +$80.9K ﹤0.01% 2557
2024
Q1 		$458K Buy
28,749
+6,933
+32% +$104K ﹤0.01% 2669
2023
Q4 		$367K Buy
21,816
+6,533
+43% +$89.3K ﹤0.01% 1667
2023
Q3 		$179K Buy
15,283
+60
+0.4% +$803 ﹤0.01% 2002
2023
Q2 		$205K Buy
15,223
+1,096
+8% +$15.8K ﹤0.01% 1975
2023
Q1 		$234K Buy
14,127
+1,127
+9% +$18.6K ﹤0.01% 1854
2022
Q4 		$242K Buy
+13,000
New +$200K ﹤0.01% 1791
2022
Q3 		– Sell
-17,275
Closed -$121K – 1764
2022
Q2 		$121K Hold
17,275
– – ﹤0.01% 1725
2022
Q1 		$143K Sell
17,275
-377
-2% -$2.67K ﹤0.01% 1770
2021
Q4 		$120K Hold
17,652
– – ﹤0.01% 1780
2021
Q3 		$94K Hold
17,652
– – ﹤0.01% 1739
2021
Q2 		$101K Buy
17,652
+543
+3% +$2.8K ﹤0.01% 1722
2021
Q1 		$79K Buy
17,109
+109
+0.6% +$433 ﹤0.01% 1565
2020
Q4 		$57K Buy
+17,000
New +$57.1K ﹤0.01% 1539

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Cetera Investment Advisers's CPRX Position: Q2 2026 in Review

Cetera Investment Advisers reduced its Catalyst Pharmaceutical (CPRX) stake by 69% in Q2 2026, selling an estimated $1.2M and leaving 17,977 shares worth $565K. The position accounts for ﹤0.01% of the portfolio, ranked #3587.

Cetera Investment Advisers first reported a position in CPRX in Q4 2020 and has held it in 22 quarters since. The position peaked at $1.45M in Q1 2026. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Cetera Investment Advisers held 17,977 shares of Catalyst Pharmaceutical worth $565K as of Q2 2026.
  • Cetera Investment Advisers sold 40,671 Catalyst Pharmaceutical shares in Q2 2026, an estimated $1.2M.
  • Catalyst Pharmaceutical made up ﹤0.01% of Cetera Investment Advisers's portfolio in Q2 2026, its #3587 holding.
  • Cetera Investment Advisers first reported a position in Catalyst Pharmaceutical in Q4 2020 and has held it in 22 quarters since.
  • Cetera Investment Advisers's Catalyst Pharmaceutical position peaked at $1.45M in Q1 2026.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Cetera Investment Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.